The pathogenesis of rheumatoid arthritis: new insights from old clinical data? (Q48029200)

7 February 2018

title

The pathogenesis of rheumatoid arthritis: new insights from old clinical data? (English)

1 reference

7 February 2018

1 reference

1

Josef S Smolen

1 reference

7 February 2018

2

Daniel Aletaha

1 reference

7 February 2018

author name string

Kurt Redlich

series ordinal

3

1 reference

7 February 2018

language of work or name

English

0 references

publication date

13 March 2012

1 reference

7 February 2018

Nature Reviews Rheumatology

published in

1 reference

7 February 2018

volume

8

1 reference

7 February 2018

issue

4

1 reference

7 February 2018

page(s)

235-243

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.23

exact match

0 references

cites work

The role of TNF alpha and IL-1 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

IL-6: from its discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Lessons from animal models of arthritis over the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

B-cell-directed therapies for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

A new class of reverse signaling costimulators belongs to the TNF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

CTLA-4 directly inhibits osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Gene therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.23

Treatments no longer in development for rheumatoid arthritis

31 March 2020

1 reference

12 December 2020

Quantitative analysis of cytokine gene expression in rheumatoid arthritis

1 reference

12 December 2020

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

12 December 2020

Interleukin-1 and interleukin-1 antagonism

1 reference

12 December 2020

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2012.23

1 reference

7 February 2018

PubMed ID

22410633

1 reference

7 February 2018